may antibodybas molecule approve regulatory author major market admit phase iii clinic trial respect total stage include name img antibodydrug concur bispecif antibody fc fusion protein radioimmunoglobulin antibody fragment immunocytokin new use disco year oncology mani exit approach involve model cell target cell checkpoint tcellredirect chime antigen receptor car cells candid current ii total interact final signifies progress made recent rout delivery include across bloodbrain barrier oral gut cellular cytosol gene viralbas thu least cell injured diver construct active impart follow next wave novel method demons field biology into diver fulfil promise treat unset medic need 